Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
MiMARK Diagnostics logo — Discovering new biomarkers for Women’s Health

MiMARK Diagnostics

Discovering new biomarkers for Women’s Health

Founded 2021 Spain Spain 24 employees Seed Total: $6.72M Biotechnology, Health Care

General Information

Company Name MiMARK Diagnostics
Founded Year 2021
Location Spain Spain +1
Employees 24
Industries Biotechnology, Health Care
Funding Stage Seed
Social

Get notified when MiMARK Diagnostics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MiMARK Diagnostics

MiMARK is a biotechnology startup with a focused mission articulated by its slogan, "Discovering new biomarkers for Women’s Health." The company is dedicated to advancing women's health care by specializing in the discovery, verification, and validation of biomarkers to develop innovative solutions for gynecological patients. Abnormal uterine bleeding is a prevalent issue, affecting 14 million women aged 50 to 75 in the EU and US annually. This demographic requires a mandatory diagnosis of endometrial cancer, as 10% of these women will be diagnosed with the disease. However, the current diagnostic method, which relies on the pathological examination of an endometrial biopsy, fails to diagnose in up to 30% of patients and provides an inaccurate diagnosis in up to 55% of cases due to the limited cellularity of the sample. In such instances, invasive diagnosis using hysteroscopy becomes necessary. MiMARK's solution, WomEC, presents a promising in vitro diagnostic tool. It is based on the determination of 5 protein biomarkers in uterine fluid samples, aiming to provide a diagnosis for 100% of patients, rule out endometrial cancer with high specificity, and offer information on the histological subtype of the tumor to guide surgical treatment. Having been founded in 2021 and headquartered in Spain, MiMARK recently secured a significant milestone with a $4.22M seed round investment on 28 November 2023. The investors involved in this latest funding round include The European Innovation Council, Nara Capital, Clave Capital, WA4STEAM, CDTI Innovación's INNVIERTE program, and Namarel Ventures. 此处的投资额、时间、地点等信息是当前分析中最重要的方面，因此我在文本中将这些信息用粗体标注出来，以突出这些关键信息。

Taxonomy: biomarkers, Women's Health, gynecological patients, uterine bleeding, endometrial cancer, pathological examination, in vitro diagnostic tool, protein biomarkers, uterine fluid samples, histological subtype, surgical treatment, diagnosis

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $4.22M 6
Nara Capital Clave Capital WA4STEAM
CDTI Innovación's INNVIERTE program, EIC Accelerator +1 		28 Nov 2023
Non Equity Assistance Unknown 1
PharmStars
04 Jul 2023
Seed Round €1.00M 2
Nara Capital
Namarel Ventures 		08 Jun 2023
Grant €1.50M - 03 Feb 2021

Latest News

View All
Barcelona’s fresh wave of innovation: 10 early-stage startups to keep an eye on — Eu-startups
Barcelona’s fresh wave of innovation: 10 early-stage startups to keep an eye on
Eu-startups Nov 04, 2024
From lab to market: 10 of the most promising EU-funded HealthTech startups — Eu-startups
From lab to market: 10 of the most promising EU-funded HealthTech startups
Eu-startups Aug 06, 2025

MiMARK Diagnostics Alternatives & Competitors

MiMARK Diagnostics vs
BIDEA LLC
BIDEA LLC Puerto Rico

BIDEA LLC is a start-up company founded in 2016 for the R&D of point-of-care technologies for cancer...

Grant
2 employees
Health Care
MiMARK Diagnostics vs
OCON Therapeutics
OCON Therapeutics Israel

We revolutionize women's quality of life and freedom of choice with healthier, safer uterine drug-de...

Series A
30 employees
Health Care, Pharmaceutical
MiMARK Diagnostics vs
Previse
Previse United States

Previse is on a mission to save lives through the prediction and earlier detection of cancer.

Grant
13 employees
Biotechnology, Medical Devices

FAQ About MiMARK Diagnostics

Discovering new biomarkers for Women’s Health
MiMARK Diagnostics was founded in 2021.
MiMARK Diagnostics is headquartered in Spain.
MiMARK Diagnostics operates in the following industries: Biotechnology, Health Care.
MiMARK Diagnostics has approximately 24 employees.
MiMARK Diagnostics has completed 4 funding rounds, raising a total of $6.72M. The latest funding stage is Seed.
Top alternatives and competitors to MiMARK Diagnostics include BIDEA LLC, OCON Therapeutics, Previse, Open Source Imaging Consortium (OSIC), VisionGate, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MiMARK Diagnostics and BIDEA LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MiMARK Diagnostics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy